Corcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow CORT
Corcept Therapeutics Incorporated (CORT) Piotroski F-score
Corcept Therapeutics Incorporated's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (2.00) |
| FY2024 | 6 | 0.00 |
| FY2023 | 6 | (2.00) |
| FY2022 | 8 | 1.00 |
| FY2021 | 7 | 1.00 |
| FY2020 | 6 | 0.00 |
| FY2019 | 6 | 0.00 |
| FY2018 | 6 | 0.00 |
| FY2017 | 6 | (2.00) |
| FY2016 | 8 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 11.71% | 19.11% | Pass | 1 |
| Positive operating cash flow | 142.00m | 198.30m | Pass | 1 |
| Rising return on assets | 11.71% | 19.11% | Fail | 0 |
| Cash flow above net income | 43.83m | 58.56m | Pass | 1 |
| Falling long-term leverage | 0.01 | 0.01 | Pass | 1 |
| Rising current ratio | 2.92 | 3.35 | Fail | 0 |
| No new shares issued | 103,862,000 | 103,232,000 | Fail | 0 |
| Rising gross margin | 98.30% | 98.39% | Fail | 0 |
| Rising asset turnover | 0.91 | 0.92 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TECH Bio-Techne Corp compare | 9 |
| BMRN BioMarin Pharmaceutical Inc. compare | 5 |
| HALO Halozyme Therapeutics, Inc. compare | 5 |
| JAZZ Jazz Pharmaceuticals PLC compare | 5 |
| IBRX ImmunityBio, Inc. compare | 4 |
| CORT Corcept Therapeutics Incorporated | 4 |
| BBIO BridgeBio Pharma, Inc. compare | 3 |
| SMMT Summit Therapeutics PLC compare | 3 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover